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ABSTRACT 
Stimulation of vascular smooth muscle (VSM) 1-adrenoceptors induces myosin 
phosphorylation and vasoconstriction via mobilisation of intracellular calcium and 
production of specific eicosanoids. Polyunsaturated fatty acid (PUFA) biosynthesis in 
VSM cells is involved, although the precise mechanism is not known. To address 
this, we characterised PUFA biosynthesis in VSM cells and determined its role in 
intracellular calcium release and eicosanoid production.  Murine VSM cells converted 
18:2n-6 to longer chain PUFA including 22:5n-6.  6 (D6d) and 5 (D5d) 
desaturase, and elongase (Elovl) 5 were expressed.  Elovl2 was not detected in 
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human, mouse or rat VSM cells, or in rat or mouse aortae, but twas not associated 
with hypermethylation of its promoter.  D6d or D5d inhibition reduced 18:3n-6 and 
20:4n-6 synthesis, respectively, and induced concentration-related decrease in 
phenylephrine-mediated calcium release, and in PGE2 and PGF2 secretion. 
Together these findings suggest that PUFA biosynthesis in VSM cells is involved 
calcium release associated with vasoconstriction.   
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1. Introduction 
Mammals can convert linoleic acid (18:2n-6) or -linolenic acid (18:3n-3) to longer 
chain polyunsaturated fatty acids (PUFA) via a series of sequential desaturation and 
carbon chain elongation reactions [1,2].  The initial, rate limiting reaction which is 
catalysed by 6-desaturase (D6d) introduces a double bond at the 6 position.  Two 
carbons are then added by the action of elongase-5.  Further desaturation at the 5 
position which is catalyzed by 5-desaturase (D5d) desaturase generates 20 carbon 
PUFA; arachidonic acid (20:4n-6) or eicosapentaenoic acid (20:5n-3).  These 20 
carbon fatty acids can be elongated to 22 carbon intermediates by elongase-5 and 
then to 24 carbon PUFA by elongase 2 or 5 activity.  An additional double bond is 
then inserted at the 6 position by D6d and the resulting PUFA are then translocated 
from the endoplasmic reticulum to peroxisomes where the carbon chain is reduced 
by 2 carbons by one cycle of fatty acid -oxidation [1]. 
 Components of the PUFA biosynthesis pathway, D6d,D5d, elongase 2 and 5 
have been detected in a number of tissues [3,4].  D6d, D5d, elongase 2 and 5 
transcripts are highly expressed in liver but also present at lower levels in and brain, 
 3
but not detected in heart [4].  D6d has also been detected in placenta, lung, skeletal 
muscle, kidney and pancreas [3,5].  D5d is expressed at markedly lower levels than 
D6d in these tissues. Synthesis of 20:4n-6 and 22:6n-3 has been reported in 
vascular endothelial [6,7] and smooth muscle cells [8], synthesis of dihomo--
linolenic acid (20:3n-6) has been reported in epidermis [9] and in macrophages [10], 
while 22:6n-3 synthesis has been detected in astrocytes [11].  The primary role of 
PUFA biosynthesis is generally assumed to support the synthesis of cell 
membranes.  In the liver PUFA biosynthesis also provides substrates for the 
synthesis of lipoproteins which serve to supply PUFA to peripheral tissues.  
However, we have shown previously that PUFA biosynthesis in vascular smooth 
muscle (VSM) cells is involved in 1-adrenoceptor (1AR)-mediated vasoconstriction 
[12].   
Phosphorylation of the myosin light chain is the principal determinant of force 
development in vascular smooth muscle (VSM) [13].  This is initiated by the release 
of calcium from intracellular stores in response to the activation of G protein-coupled 
receptors by neuroendocrine factors, for example binding of phenylephrine (Pe) to 
1AR.  This leads to activation of protein kinase C that, via various second 
messengers including eicosanoids, facilitating efflux of calcium into the cytoplasm, 
producing calcium sensitisation [13].  Increased myosin phosphorylation also 
involves inhibition of myosin light chain phosphatase (MLCP) [14], hence preventing 
dephosphorylation of myosin, via the activities of atypical protein kinase C (aPKC) 
[15,16] and rhoA kinase [17,18].  Non-esterified 20:4n-6 has been shown to inhibit 
MLCP leading to increased myosin light chain phosphorylation and impaired 
vasodilatation in VSM independent of intracellular calcium concentration and the 
production of eicosanoid synthesis [19].  However, this effect was inhibited by non-
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enzymatic oxidation of 20:4n-6 indicating that intact 20:4n-6, and not its metabolites, 
was responsible for inhibition of MLCP [19].  A calcium independent phospholipase 
A2 has also been implicated in calcium sensitisation in VSM cells [20]. 
We have shown previously that SC26196, a specific inhibitor of D6d [8,21], or 
sesamin, a specific inhibitor of D5d [22], reduced Pe-mediated vasoconstriction in rat 
aortae and human femoral arteries ex-vivo by approximately 75% irrespective of the 
presence or absence of the vascular endothelium [12].  These findings suggest that, 
in addition to any role in maintaining membrane fatty acid composition, PUFA 
biosynthesis in VSM cells is linked closely to the process of 1AR-mediated force 
generation. Treatment of isolated rat aortae with SC26196 reduced selectively the 
secretion of the pro-vasoconstriction eicosanoids prostaglandin (PG)F2, PGE2 and 
thromboxane (Tbx) B2 [12].  Since eicosanoids acting via thromboxane receptors in 
VSM are potent agonists for vasoconstriction [23], these findings suggest that one 
possible role for PUFA biosynthesis in developing VSM tone could be to generate a 
source of substrates for the formation of vasoactive prostanoids.  However, it is not 
known whether PUFA biosynthesis in VSM cells is induced by Pe, which would 
suggest coordinated regulation of PUFA formation with dynamic changes in blood 
flow, or whether it is constitutive and hence possibly involved in vascular 
homeostasis.  Furthermore, it is not known whether PUFA biosynthesis is in involved 
directly in Pe-mediated calcium release or downstream of this event, for example by 
providing substrates that influence myosin kinase or phosphatase activities.  To 
address this, we characterised PUFA biosynthesis in VSM cells in vitro and 
measured the effect of Pe on the activity of the PUFA biosynthesis pathway.  We 
also determined the effect of inhibiting PUFA biosynthesis on Pe-induced release of 
intracellular calcium and production of pro-vasoconstriction eicosanoids.   
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2.  Materials and methods 
2.1  Materials 
SV40-immortalised murine vascular smooth muscle (MOVAS) cells were from 
American Type Culture Collection (Manassas, Virginia, USA), murine hepatoma cells 
(Hepa1-6) and human hepatocarcinoma cells HepG2 were from European Collection 
of Cell Cultures (Porton Down 
Salisbury, UK) and human primary aortic smooth muscle (HASM) cells were from 
Life Technologies.  [1-13C]-18:2n-6 ethyl ester was purchased from Cambridge 
Isotope Laboratories (Tewksbury, Massachusetts, USA).  Primers for real time PCR 
were from Qiagen (Manchester, UK).  Bespoke pyrosequencing PCR and 
sequencing primers were purchased from Biomers (Ulm, Germany).  All other 
reagents were obtained from Sigma or PAA, with noted exceptions.  Mouse and rat 
aorta and liver tissue that were used to confirm findings in immortalized cells were 
archived specimens collected from adult animals that had been maintained 
throughout life on RM1 standard chow diet (Special Diets Services, Witham, Essex, 
UK) and which were stored at -80oC.  
 
2.2  Measurement of PUFA biosynthesis 
n-6 PUFA biosynthesis was measured directly by the incorporation of [13C] from 
18:2n-6 into longer chain metabolites or indirectly from the proportions of individual 
n-6 PUFA in total cell lipid extracts following treatment with linoleic acid.  
In order to measure incorporation of [13C] into n-6 PUFA, HEPa1-6 or MOVAS 
cells were seeded in Dulbecco’s Modified Eagle’s Medium (DMEM) containing fetal 
bovine serum (10% (w/w)) at sub-confluency and allowed to attach for 24 hours.  [1-
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13C]18:2n-6 ethyl ester (10 moles/l) and 18:2n-6 (90 moles/l, vehicle) were added 
and the cultures which were maintained at 37oC in an atmosphere containing 5% 
(v/v) CO2 for 48 hours.  In some experiments, Pe (100 mol/l) was added to the 
MOVAS cell cultures for the last 30 minutes.  This Pe concentration has been shown 
to induce vasoconstriction in ex-vivo preparations of rat and human arteries [12]. At 
the end of the incubation period, cells were washed with ice cold Hank’s Balanced 
Salt Solution (HBSS).  0.8ml NaCl (0.9% w/v) was then added and the cells scraped 
into a glass tube and placed on ice.  An aliquot was reserved for measurement of 
total cell protein using the Pierce® BCA Protein Assay kit (Thermo Scientific). 
Incubation of cells with unlabelled 18:2n-6 were carried out in an identical 
manner to those which used [13C]18:2n-6 except 18:2n-6 was added to a final 
concentration of 100 mol/l.   
 
2.3  Measurement of stable isotope incorporation by gas chromatography 
combustion isotope-ratio mass spectrometry 
Total lipids were extracted with chloroform and methanol [24] using heptadecanoic 
acid (10 g) as internal standard.  Fatty acids were converted to fatty acid methyl 
esters (FAMEs) by incubation with methanol containing 2% (v/v) sulphuric acid [25].  
The concentration of individual PUFA was determined by gas chromatography [10].  
Incorporation of [13C] into n-6 PUFA was measured by gas chromatography 
combustion isotope-ratio mass spectrometry as described [26].  Briefly, FAMES were 
separated on a gas chromatograph (Thermo trace GC ultra, Bremen, Germany) 
equipped with a DB-wax column (30 m x 0.25 mm x 0.25 µm) (Agilent, UK). FAMES 
were then oxidatively combusted to CO2, which was ionised and detected using a 
Thermo Finnigan DeltaPlus XP mass spectrometer allowing the ratio of 13CO2/12CO2 
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from the combusted product to be measured, calibrated against  a certified standard 
(eicosanoic acid FAME, Department of Geological Sciences, Indiana University, 
Bloomington, IN). FAMES were identified from retention times of standards (Sulpelco 
37 component  FAME mix and individual FAME standards, Sigma-Aldrich, Dorset, 
UK). 
 
2.4  Measurement of fatty acid composition by gas chromatography 
Total lipids and FAMEs were prepared as above.  The proportions of individual fatty 
acids were measured by gas chromatography using an Aglient 6890 gas 
chromatograph equipped with a BPX70 fused silica capillary column (30m x 0.25 mm 
x 0.25 m) (SGE) and flame ionisation detection [12].  FAMEs were identified by 
their retention times relative to standards and quantified using Chemstation software 
(Agilent). 
 
2.3 Measurement of mRNA expression 
Total RNA was isolated from cells using Tri-reagent (Sigma) as described [12]. 
Complementary DNA was prepared and amplified using real-time RTPCR, which 
was performed as described using SYBR Green Jumpstart Ready Mix (Sigma) in a 
final volume of 25 l [12].  RTPCR primers are listed in Table 1.  All samples were 
analysed in duplicate. Cycle parameters were 95oC for 2 minutes then 40 cycles of 
95oC for 30 seconds, 55oC (cyclophilin, FADS1, FADS2, ELOVL2 and ELOVL5) for 1 
minute and 72oC for 1 minute. Expression was determined by the standard curve 
method [27] using cyclophilin (Qiagen, West Sussex, UK) as the reference gene. 
 
2.4   Measurement of the DNA methylation status of the ELOVL2 promoter 
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Genomic DNA was extracted from VSM and liver cells, and mouse aortae and liver 
samples as described [28].  Briefly, DNA was treated with sodium metabisulphite 
using the EZ DNA methylation kit (ZymoResearch).  The pyrosequencing reaction 
was carried out using primers listed in Table 2.  Modified DNA was amplified using 
KAPA2G Robust Hot Start Taq DNA polymerase (Labtech).  The amplified products 
were immobilised on streptavidin–sepharose beads (GE Healthcare UK Ltd.), 
washed, denatured and released into annealing buffer containing the sequencing 
primers (Table 2) (Biomers, Söflinger, Germany).  Pyrosequencing was carried out 
using an SQA kit on a PSQ 96MA pyrosequencer (Biotage, Uppsala, Sweden).  The 
percentage methylation at each CpG locus was determined using the Pyro Q CpG 
software (Biotage). 
 
2.5  Measurement of calcium release 
MOVAS cells were seeded in DMEM at approximately 40,000 per well in a black-
sided, clear base 96 well plate (Greiner Bio-One Ltd) and allowed to attach for 24 
hours.  The Screen Quest Fluo-8 Medium kit was prepared according to the 
manufacturer’s instructions (AAT Bioquest). Fluo-8 dye was dissolved in 
dimethylsulphoxide (DMSO) and then mixed with HBSS and 10x pluronic F127.  The 
cell culture medium was replaced with dye solution and either SC26196 or sesamin 
dissolved in HBSS containing DMSO (0.1% v/v) or DMSO vehicle solution alone 
(0.1% v/v) were then added.  Cells were incubated in the dark for 30 minutes at 37oC 
and then for a further 30 minutes at room temperature.  In some experiments, Pe (10 
mol/l) was added for 30 seconds prior to reading the plate using a Thermo 
Labsystems Fluoroscan at an excitation wavelength  = 485 nm and emission 
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wavelength  = 538 nm.  A23187 calcium ionophore (500 nmoles/l) was used as the 
positive control.  
 
2.6  Measurement of eicosanoid concentrations  
MOVAS cells were seeded at approximately 60,000 cells per well in 6 well plates in 
DMEM and allowed to attach as before.  Either SC26196 (200 nmol/l to 1 mol/l) or 
sesamin (10 mol/l to 20 mol/l) was added and the cells incubated for a further 48 
hours.  The medium was then replaced with DMEM without fetal bovine serum 
containing either SC26196 or sesamin, with or without Pe (100 mol/l).  Cells were 
maintained for a further 30 minutes.  The culture supernatant was collected, frozen 
immediately on dry ice and the samples stored at -80oC.  The concentrations of 12-
hydroxyicosa-5,8,10,14-tetraenoic acid (HETE) (Abcam), PGE2, PGF2 and Tbx B2 
(Cayman Chemical Company) were measured by ELISA as instructed by the 
manufacturer.    
 
2.7 Statistical analysis 
Statistical analysis was carried out using SPSS (Version 21.0, IBM, Armonk, NY: 
IBM Corp.).  Data from dose-response experiments was analysed by 1-way ANOVA 
with Dunnett’s post hoc test to compare the effect of each concentration of inhibitor 
to control.  Experiments involving single concentrations of inhibitors were analysed 
by Student’s unpaired t test. Statistical significance was assumed at probabilities 
less than 0.05.  The sample size of ten replicates was sufficient to detect a 10% 
difference in the primary outcome measures; mRNA expression and synthesis of 
deuterated fatty acids, with a statistical power of 85% and probability of P < 0.05 
[12,29].   
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Results 
3.1  n-6 PUFA biosynthesis 
18:2n-6, 20:3n-6, 20:4n-6 and 22:4n-6 were the major [13C]-labelled fatty acids in 
MOVAS and in Hepa1-6 cells (Figure 1A).  The amount of [13C]18:2n-6 was 1.8 fold 
greater (P = 0.009) in Hepa1-6 cells compared to MOVAS cells.   Incorporation of 
[13C] into 20:4n-4 was 2.4-fold (P=0.04) and in to 22:4n-6 was 2.7-fold (P=0.02) 
greater in MOVAS cells than Hepa1-6 cells, but the enrichment in 20:3n-6 did not 
differ between cell types (Figure 1A).  Calculation of product to precursor ratios as 
proxy measures of enzyme activities for individual reactions indicated that 
conversion of 18:2 to 20:3n-6 (marking combined D6d and elongase-5 activities) was 
significantly greater in MOVAS cells compared to Hepa1-6 cells (Figure 1B).  The 
ratio of 20:4n-6 to 20:3n-6 (marking D5d activity) was also significantly greater (2.5-
fold) in MOVAS cells compared to Hepa1-6 cells (Figure 1B).  However, there was 
no significant difference between cell types in the ratio of 22:4n-6 to 20:4n-6 
(marking elongase-2 and/or 5 activities).  No incorporation of [13C] into 22:5n-6 
above background was detected. There was no significant effect of treating MOVAS 
cells with Pe on [13C] enrichment of individual PUFA (Figure 1A).  
 
3.2  mRNA expression of Fads and Elovl genes 
Fads1 and 2, and Elovl 5 mRNA expression was detected in mouse and rat aorta, in 
MOVAS cells and in primary HASM cells (Figure 2 A).  Because of potential 
differences in RTPCR primer efficiency, comparisons of mRNA expression of each of 
the transcripts were only possible within a species.  There were significant 
differences in Fads1 and Fads2 expression between mouse-derived cells and 
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tissues (ANOVA both P<0.0001).  Fads1 and Fads2 mRNA expression was higher in 
MOVAS and Hepa1-6 cells than in the corresponding primary tissue (Figure 2A).  
However, there were no significant differences in Fads1 or Fads2 expression 
between MOVAS and Hepa1-6 cells or between mouse aorta and liver.  Elovl5 
expression differed between mouse-derived tissues (ANOVA P = 0.0002).  The level 
of Elovl5 was lower in mouse aorta than in MOVAS cells, but was similar in Hepa1-6 
cells and liver.   Elovl5 expression in Hepa1-6 cells and liver was lower than in 
MOVAS cells and higher than in aorta.   Elovl2 was not detected in either mouse or 
rat aorta, or in MOVAS or HASM cells (Figure 2A-C), but was readily detected in 
Hepa1-6 cells, and in mouse and rat liver (Figure 2A,B).     
 
3.3  DNA methylation of the 5’-regulatory region of Elovl2 
In order to determine whether the silencing of Elovl2 in vascular-derived cells was 
due to the methylation status of its promoter, twenty-nine CpG loci were measured in 
a region between -117 and -368 bp from the transcription start of the gene (Figure 
3).   There were significant differences in methylation of three CpG loci between 
mouse aorta and liver (Figure 3A).  Eleven CpG loci had lower methylation in 
MOVAS cells than in Hepa1-6 cells in the region between -368 and -212bp from the 
Elovl2 transcription state site (Figure 3B).  Conversely, six CpG loci had higher 
methylation in MOVAS cells than in Hepa1-6 cells in the region between -135 and -
117 bp from the Elovl2 transcription start site (Figure 3B).  There were no significant 
differences in the level of methylation between MOVAS and Hepa1-6 cells in the 
intervening region between -208 and -156 bp.  There were marked differences in the 
overall pattern of DNA methylation of the Elovl2 5’-regulatory region between aorta 
and liver, and MOVAS and Hepa1-6 cells (Figure 3A,B).  In aorta and liver, the level 
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of methylation of the CpG loci in the region that was measured was relatively low, 
and below the detection limit of the assay for the majority of loci.  Conversely, in 
MOVAS and Hepa1-6 cell, the region between -368 and -239 bp was highly 
methylated compared to aorta and liver.  The level of methylation of the region 
between -135 and -117 bp was markedly greater in MOVAS cells, but not Hepa1-6 
cells, than in aorta or liver.   
 
3.4  The effect of D6d or D5d inhibition on Pe-mediated calcium release in MOVAS 
cells 
Both SC26196 and sesamin reduced Pe-mediated calcium release compared to the 
DMSO vehicle (both ANOVA P<0.0001).  SC26196 reduced Pe-mediated calcium 
release in a dose-related manner by 19% (0.5 mol/l) and by 33% at 1.0 mol/l in 
MOVAS cells (Figure 4A).  Similarly, treatment with sesamin (10 mol/ and above) 
reduced Pe-mediated calcium release by 32% (Figure 4B). 
 
3.5  The effect of D6d or D5d inhibition on Pe-mediated eicosanoid release in 
MOVAS cells    
Treatment of MOVAS cells with SC26196 induced a statistically significant, 
concentration-related decrease in Pe-mediated secretion of PGE2 and PGF2  
(ANOVA P = 0.0152 and P = 0.008, respectively) such that compared to Pe alone, 
treatment with 1mol/l SC26196 reduced PGE2 concentration by 53% and PGF2 
concentration by 39.3% (Figure 5 A,B).  In contrast, there was no significant effect of 
treatment with SC26196 on Pe-mediated 12-HETE or Tbx B2 secretion (Figure 5 
C,D).  
 Treatment of MOVAS cells with sesamin induced a statistically non-
significant, concentration-related trend towards lower PGE2 secretion (P= 0.078) and 
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a statistically significant (P = 0.007) decrease in PGF2 secretion (Figure 5 E,F).  
Compared to Pe alone, treatment with 20 mol/l sesamin reduced PGE2 
concentration by 37% and PGF2 concentration by 67% (Figure 5 A,B).  There was 
no statistically significant effect of treatment with sesamin on Pe-mediated 12-HETE 
or Tbx B2 secretion (Figure 5 G,H).     
 
4. Discussion 
4.1  Characterisation of n-6 PUFA biosynthesis in VSM cells 
The present findings show that VSM cells are able to synthesise a range of longer 
chain, more unsaturated fatty acids from 18:2n-6 and that PUFA biosynthesis is 
involved in Pe-mediated release of calcium from intracellular stores and production 
of specific eicosanoid species. 
 We have shown previously that inhibition of D6d and D5d activity in ex-vivo 
preparations of rat aortae and in human femoral arteries reduced 1AR-mediated 
vasoconstriction and the secretion of specific pro-vasoconstrictor eicosanoids [12].  
Furthermore, PUFA biosynthesis activity associated with vasoconstriction was 
localised to VSM cells rather than the vascular endothelium [12].  In order to 
investigate further the function of PUFA biosynthesis in vasoconstriction, we 
characterised the activity of this pathway in VSM cells in vitro.  The findings of the 
present study support our previous observations by demonstrating that MOVAS cells 
converted 18:2n-6 to longer chain PUFA, including the longest chain metabolite of 
the n-6 PUFA series 22:5n-6.  This is in agreement with the single previous report of 
n-6 PUFA metabolism in VSM cells from human aortae [8].  Previous studies have 
shown that 18:2n-6 can be converted to 20:4n-6 in human umbilical vein endothelial 
cells in vitro [6,7].   However, the extent of conversion appears to be limited to 20:4n-
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6 with no detectable synthesis of longer chain metabolites [6].  Overall, these 
findings are consistent with differential function of PUFA biosynthesis between 
vascular endothelial and smooth muscle cells. 
 
4.2  mRNA expression of genes involved in PUFA biosynthesis and DNA methylation 
of Elovl2 
The expression of Fads1 and Fads2 was similar in MOVAS and Hepa1-6 cells and in 
mouse aortae and liver, although the levels of these transcripts were lower in the 
tissues compared to the cell lines.  However, synthesis of 20:4n-6 and 22:4n-6 was 
greater in MOVAS cells than in Hepa1-6 cells.  Thus the level of PUFA biosynthesis 
involves additional regulatory factors controlling transcription and/ or translation.  
Elovl5 expression was markedly higher in MOVAS compared to aortae, but similar to 
Hepa1-6 cells and in liver.  This implies that PUFA biosynthesis activity in the 
MOVAS cells and in Hepa1-6 cells may not be completely representative of aortae 
and liver, respectively.  However, despite this difference, PUFA biosynthesis may be 
at least as active in VSM as in liver.  PUFA biosynthesis is highly active in liver as it 
provides substrates for cell membrane and lipoprotein synthesis such that Fads2 and 
Fads1  mRNA expression is markedly higher in liver compared to other tissues, with 
the exception of testis [3,30].  If so, one possible implication is that the PUFA 
biosynthesis contributes to other processes in VSM in addition to maintaining cell 
membrane composition. 
Elovl2 mRNA was not detected in MOVAS cells, rat aortae or primary HASM 
cells, but was detected readily in Hepa1-6 cells, and in mouse and rat liver.  One 
interpretation of this finding is that conversion of 20:4n-6 to 22:4n-6 and 22:4n-6 to 
24:4n-6 involves another elongase, although we were not able to identify which 
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enzyme catalyses these reactions.  However, the possiblity that Elovl2 was 
expressed at a level below the limit of the RTPCR assay cannot be discounted 
completely.  The reason for the apparent differential use of elongase 2 between VSM 
and liver is not known.  It is possible that the use of an alternative elongase is 
important for the regulation of PUFA biosynthesis related to a specific function in 
VSM. 
DNA methylation of the 5’-regulatory regions (5’-RR) of genes is associated 
generally with suppression of transcription [31].  We investigated whether the 5’-RR 
of Elovl2 was hypermethylated in vascular cells compared to liver.  The findings 
show that the level of methylation of 5’-RR of Elovl2 was close to the lower limit of 
detection of the sequencing technique (5%) [12].  Thus Elovl2 was essentially 
unmethylated in both mouse aortae and in liver.  The pattern of DNA methylation of 
Elovl2 5’-RR was similar in MOVAS and Hepa1-6 cells in the region between -638 
and -156 bp, although methylation of CpG loci in the sequence furthest from the 
transcription start site was higher in Hepa1-6 compared to MOVAS cells.  In contrast, 
methylation of CpG loci in the most proximal region was higher in MOVAS compared 
to Hepa1-6 cells.  However, the pattern of DNA methylation of MOVAS and Hepa1-6 
cells differed markedly from aortae and liver, respectively, which may represent an 
effect of adaptation to in vitro culture.   Together, these findings suggest that 
suppression of Elovl2 transcription in VSM cells and in aortae was not associated 
with hypermethylation of the gene, although it is possible that sequences either 
closer to the TSS or more distal to region that was analysed could have been be 
differentially methylated.    
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4.3  The role of PUFA biosynthesis in intracellular calcium release and in eicosanoid 
secretion in VSM cells 
SC26196 and sesamin are structurally distinct, specific inhibitors of D6d and D5d, 
respectively [8,21,22].  As expected, treatment of MOVAS cells with SC26196 
increased the proportion of 18:2n-6 and decreased the proportions of all down-
stream metabolites in total cell lipids, consistent with specific inhibition of D6d, which 
is consistent with Harmon et al. [8].  Furthermore, treatment with sesamin increased 
the proportions of 18:2n-6, 18:3n-6 and 20:3n-6 in total cells lipids which is 
consistent with specific inhibition of D5d [22].  Together these findings show that 
SC26196 and sesamin are selective inhibitors of PUFA biosynthesis in VSM cells. 
 Both SC26196 and sesamin induced a concentration-related inhibition of Pe-
mediated PGE2 and PGF2 secretion, although this did not reach statistical 
significance for PGF2 in cells treated with sesamin.  However, there was no 
significant effect of these inhibitors on the secretion of 12-HETE or TbxA2 (measured 
as it stable degradation production TbxB2).  These results are consistent with our 
previously observations that inhibition of D6d by SC26196 in rat aortae reduced the 
secretion of the pro-vasoconstrictor eicosanoids PGE2, PGF2 and TbxB2, although 
there was no significant effect on 12-HETE secretion [12].  However, the present 
results extend these findings by showing that inhibition of D5d has similar effects on 
PGE2 and PGF2 secretion as D6d inhibition.  PGE2 can be converted to PGF2 by 
prostaglandin E 9-ketoreductase activity, as well as direct synthesis of both PGE2, 
and PGF2 from PGH2.  Thus possible mechanisms by which inhibition of D6d or 
D5d may reduce PGE2, and PGF2 secretion is by reduction in the availability of 
20:4n-6 for synthesis of PGH2 by cyclooxygenase activity.   If so, it would be 
expected that TbxB2 secretion would also be reduced.  Our previous experiments 
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that used mass spectrometry to analyse supernatants from ex vivo preparations of 
rat aortae stimulated with Pe showed that inhibition of D6d reduced TbxB2 
concentration [12] and so it is possible that the ELISA assay used here was not 
sufficiently sensitive to detect TbxB2 in culture supernatants from Pe-stimulated 
MOVAS cells.  12-HETE is produced by 5-lipoxygenase activity.  Thus one possible 
explanation for the differential effect of inhibition of PUFA biosynthesis by SC26196 
and sesamin is that 20:4n-6 synthesised de novo is used preferentially by 
cyclooxygenase, compared, for example, to 20:4n-6 derived pre-formed from the 
culture medium.  
SC26196 reduced Pe-mediated calcium release in a concentration-related 
manner. Furthermore, sesamin also inhibited Pe-mediated calcium release.  These 
findings are consistent with our previous observations that PUFA biosynthesis de 
novo in VSM cells is involved centrally in 1AR-mediated vasoconstriction [12].  
However, the present findings extend the previous observations by demonstrating 
the involvement of PUFA biosynthesis in intracellular calcium release.  Although both 
SC26196 and sesamin have been shown to inhibit D6d and D5d specifically 
[8,21,22] it is possible that these inhibitors may have reduced calcium release via an 
effect on another pathway.  However, the structural differences between SC26196 
and sesamin suggest that it is unlikely, although further experiments are required to 
provide conclusive findings.            
 Contraction of VSM involves release of calcium from internal stores as a 
result of the activation of G protein receptors leading to calcium sensitisation [32,33]. 
This process also involves inhibition of MLCP [14] by a mechanism involving non-
esterified 20:4n-6.  The present findings are consistent with these observations, but 
extend these findings by showing that 20:4n-6 synthesised de novo is involved in Pe-
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mediated calcium sensitisation.  Thus we suggest cautiously that one interpretation 
is that 20:4n-6 synthesised de novo may be the principle source of 20:4n-6 that 
inhibits MLCP and acts a substrate for the synthesis of pro-vasoconstriction 
eicosanoids that induce intracellular calcium release (Figure 6).  However, this model 
requires further investigation.  
Impaired vasodilatation and increased vasoconstriction are causal processes 
in a number of pathological conditions of major health importance and involve 
impaired regulation of calcium sensitisation [34].  Identification of a novel novel 
component of the pathway that regulates release in VSM cells raises the possibility 
of new therapeutic interventions in vascular disease. 
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Figure 1.  Synthesis of n-6 PUFA in MOVAS and Hepa1-6 cells 
Values are mean SEM for n=10 replicate cultures.  (A) Incorporation of [13C] into n-6 
PUFA in MOVAS cells in the absence or presence of Pe, or into Hepa1-6 cells. 
Statistical analysis was by 1-way ANOVA with Dunnett’s post hoc pairwise test.  (B) 
Product to precursor ratios of [13C]-labelled n-6 PUFA in MOVAS and Hepa1-6 cells 
representing proxy measures of; D6d plus elongase 5 activities (20:3n-6/18:2n-6), 
(D5d activity 20:4n-6/20:3n-6) or D5d plus elongase 2 or 5 activities (22:4n-6/20:3n-
6).  The effect of treatment with (C) SC26196 (200nM) or (D) sesamin (20µM) on the 
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n-6 PUFA content of MOVAS cells.  Panels B-D, means that were statistically 
significantly different from control cultures by Student’s t test are indicated by 
*P<0.05, **P<0.01, ***P<0.001. 
 
Figure 2.  mRNA expression of genes involved in PUFA biosynthesis.  Values are 
mean ! SEM (n=10 replicates).  (A) Mouse cells and tissues, (B) rat tissues and 
(C) human primary vascular smooth muscle cells.   Panel (A), means that were 
statistically significantly different (P<0.05) from MOVAS cells for each genes by 1-
way ANOVA with Dunnett’s post hoc pairwise comparisons, except for Elovl2 where 
Hepa1-6 cells and liver were compared by Student’s unpaired t test, are indicated by 
different letters.  Panel B, means that were significantly different between cells and 
tissues by Student’s unpaired t test are indicated by *P<0.05, **P<0.01, ***P<0.001.  
Panel (C), no statistical analysis was carried out.  
 
Figure 3.  Methylation of individual CpG loci in the 5’-regulatory regions of Elovl2.  
Values are mean ! SEM (n=10 replicates).  (A) mouse tissues and (B) mouse 
cells.  CpG loci are indicated relative to the transcription start  site (TSS).  Dotted 
lines indicate the limited of detection.  Means that were significantly different 
between tissues or between cell types by Student’s unpaired t test are indicated by 
*P<0.05, **P<0.01, ***P<0.001.   
 
Figure 4.  The effect of inhibition of delta-6 or delta-5 desaturase on phenylephrine-
mediated calcium release in MOVAS cells.  Values are mean ! SEM (n=10 
replicates). (A) Treatment with SC26196, (B) treatment with sesamin.   Means that 
were significantly different from vehicle alone by 1-way ANOVA with Dunnett’s post 
hoc test are indicated by *P<0.05, **P<0.01, ***P<0.001.   
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Figure 5.  The effect of treatment with or sesamin on the phenylephrine-mediated 
secretion of PGE2, PGF2, TbxB2 and12-HETE. Values are mean ! SEM (n=10 
replicates).  Means that were significantly different from vehicle alone by 1-way 
ANOVA with Dunnett’s post hoc test are indicated by *P<0.05, **P<0.01, ***P<0.001.   
 
Figure 6.  A model for the role of PUFA biosynthesis de novo in calcium sensitisation 
in vascular smooth muscle cells.  A detailed explanation is presented in the text.  
aPKCz, atypical protein kinase C-zeta; ciPLA2, calcium-indpendent phospholipase 
A2; D5d, delta-5 desaturase; D6d, delta-6 desaturase; MLCP, myosin light chian 
phosphatase.  GO = activation,  = inhibition. 
 
 
HIGHLIGHTS 
 
Vasoconstriction involves polyunsaturated fatty acid synthesis in vascular smooth 
muscle cells. 
 
We investigated the underlying mechanism in vascular smooth muscle (VSM) cells in 
vitro. 
 
6 or 5 desaturase inhibition reduced phenylephrine-induced calcium release.  
 
6 or 5 desaturase inhibition also reduced PGE2, and PGF2 secretion.     
 
We propose a model for the role of PUFA biosynthesis in calcium sensitisation in 
VSM.  
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